Diacarta

HAYWARD, CA 94545
6 Employees

SBIR Award Summary

Total Number of Awards 5
Total Value of Awards $1.74MM
First Award Date 08/19/08
Most Recent Award Date 09/19/16

Key Personnel

Last Name Name Awards Contact
Zhang Dr. Aiguo Zhang 4 Message
Ma Dr. Yunqing Ma 1
Zhang Lulu Zhang 1 Message
Zhang Aiguo Zhang 1

5 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/19/16 - 06/18/17

In different individuals exposed to radiation, radiation will cause variable levels of rapid combined tissue death, cell apoptosis and necrosis leading to toxicity. This acute tissue loss correlates with radiation injury. DiaCarta?s RadTox QuantiDNATMdiagnostic product measures tissue loss and is related to radiation dose, field size, known sens...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-093
Budget: 03/01/13 - 02/28/14

DESCRIPTION (provided by applicant): For victims of gastrointestinal (GI) radiation exposure and concomitant GI syndrome, DiaCarta's fibroblast growth factor-peptide (FGF-P) is a product that will not only reduce depopulation and improve reepithelialization of the small bowel but also support bone marrow function. It could be the crucial factor...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-093
Budget: 03/01/12 - 02/28/13

DESCRIPTION (provided by applicant): For victims of gastrointestinal (GI) radiation exposure and concomitant GI syndrome, DiaCarta's fibroblast growth factor-peptide (FGF-P) is a product that will not only reduce depopulation and improve reepithelialization of the small bowel but also support bone marrow function. It could be the crucial factor...

Phase 2 STTR

Institution: University of Rochester

Agency: Defense Advanced Research Projects Agency
Topic: ST081-003
Budget: 06/15/10 - 06/14/12

Early detection of virulent infectious pathogens is critical to blocking the devastating epidemic spread of the pathogen and the potential harm this could have on our armed forces and general populations. In Phase I, we have utilized the state-of-the-art QuantiGene 2.0 technology to establish an assay for the sensitive quantification of SARS (ep...

Phase 1 STTR

Institution: University of Rochester

Agency: Defense Advanced Research Projects Agency
Topic: ST081-003
Budget: 08/19/08 - 10/31/09

The development of early detection methods to aid in the identification of virulent infectious pathogens is of strategic importance so that exposed warfighters and other individuals can be treated early or appropriately quarantined. We are currently developing a nucleic acid-based assay that can selectively and sensitively detect and quantify th...